Symbols / RGNX
RGNX Chart
About
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 532.55M |
| Enterprise Value | 566.19M | Income | -193.88M | Sales | 170.44M |
| Book/sh | 2.02 | Cash/sh | 4.46 | Dividend Yield | — |
| Payout | 0.00% | Employees | 371 | IPO | — |
| P/E | — | Forward P/E | -4.83 | PEG | — |
| P/S | 3.12 | P/B | 5.21 | P/C | — |
| EV/EBITDA | -3.89 | EV/Sales | 3.32 | Quick Ratio | 2.27 |
| Current Ratio | 2.38 | Debt/Eq | 253.59 | LT Debt/Eq | — |
| EPS (ttm) | -3.46 | EPS next Y | -2.18 | EPS Growth | — |
| Revenue Growth | 43.00% | Earnings | 2026-05-11 | ROA | -21.93% |
| ROE | -107.00% | ROIC | — | Gross Margin | -45.86% |
| Oper. Margin | -189.99% | Profit Margin | -113.75% | Shs Outstand | 50.62M |
| Shs Float | 43.00M | Short Float | 14.38% | Short Ratio | 5.13 |
| Short Interest | — | 52W High | 16.19 | 52W Low | 5.04 |
| Beta | 1.14 | Avg Volume | 967.85K | Volume | 140.31K |
| Target Price | $27.82 | Recom | Buy | Prev Close | $10.38 |
| Price | $10.52 | Change | 1.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$27.82
Mean price target
2. Current target
$10.52
Latest analyst target
3. DCF / Fair value
$-28.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.52
Low
$12.00
High
$50.00
Mean
$27.82
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-09 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2026-03-06 | main | Morgan Stanley | Overweight → Overweight | $17 |
| 2026-02-10 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2026-02-10 | main | Goldman Sachs | Neutral → Neutral | $12 |
| 2026-02-10 | main | Morgan Stanley | Overweight → Overweight | $18 |
| 2026-02-10 | main | Chardan Capital | Buy → Buy | $50 |
| 2026-01-29 | main | Chardan Capital | Buy → Buy | $52 |
| 2025-12-19 | main | Stifel | Buy → Buy | $45 |
| 2025-12-15 | main | Leerink Partners | Outperform → Outperform | $20 |
| 2025-11-20 | main | Chardan Capital | Buy → Buy | $52 |
| 2025-11-07 | main | RBC Capital | Outperform → Outperform | $19 |
| 2025-10-07 | reit | HC Wainwright & Co. | Buy → Buy | $34 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $34 |
| 2025-09-08 | main | Chardan Capital | Buy → Buy | $52 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $34 |
| 2025-08-08 | main | RBC Capital | Outperform → Outperform | $17 |
| 2025-08-08 | main | Barclays | Overweight → Overweight | $37 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $52 |
| 2025-06-09 | main | Chardan Capital | Buy → Buy | $52 |
| 2025-04-17 | main | Goldman Sachs | Neutral → Neutral | $12 |
- $RGNX stock is up 18% today. Here's what we see in our data. - Quiver Quantitative Mon, 09 Mar 2026 14
- Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com Nigeria ue, 10 Mar 2026 04
- (RGNX) and the Role of Price-Sensitive Allocations - Stock Traders Daily ue, 10 Mar 2026 03
- RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - Stock Titan hu, 05 Mar 2026 19
- Assessing Where Regenxbio Stands After FY25 Results (NASDAQ:RGNX) - Seeking Alpha Fri, 06 Mar 2026 16
- Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus Mon, 09 Mar 2026 11
- RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire Fri, 06 Mar 2026 13
- Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance hu, 05 Mar 2026 13
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Fri, 06 Mar 2026 15
- Gene Therapy Stock Crashes On 'Confusing And Unexpected' News - Investor's Business Daily Wed, 28 Jan 2026 08
- REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX - Morningstar Wed, 04 Mar 2026 14
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX - PR Newswire hu, 05 Mar 2026 21
- Biotech REGENXBIO schedules three March investor talks, with webcast access - Stock Titan Mon, 02 Mar 2026 12
- Morgan Stanley Lowers Price Target for RGNX but Maintains Overwe - GuruFocus Fri, 06 Mar 2026 16
- Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance hu, 26 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 225000 | 2945250 | — | Conversion of Exercise of derivative security at price 13.09 per share. | MILLS KENNETH THOMAS | Director | — | 2026-01-27 00:00:00 | D |
| 1 | 144864 | — | — | Stock Award(Grant) at price 0.00 per share. | SIMPSON CURRAN M | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 2 | 73749 | — | — | Stock Award(Grant) at price 0.00 per share. | CHRISTMAS PATRICK J. II | Officer | — | 2026-01-06 00:00:00 | D |
| 3 | 65847 | — | — | Stock Award(Grant) at price 0.00 per share. | PAKOLA STEPHEN J | Officer | — | 2026-01-06 00:00:00 | D |
| 4 | 73749 | — | — | Stock Award(Grant) at price 0.00 per share. | CHAN MITCHELL | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 5 | 65847 | — | — | Stock Award(Grant) at price 0.00 per share. | MALZAHN CRAIG | Chief Technology Officer | — | 2026-01-06 00:00:00 | D |
| 6 | 20811 | 262635 | — | Sale at price 12.62 per share. | SIMPSON CURRAN M | Chief Executive Officer | — | 2025-10-09 00:00:00 | D |
| 7 | 7624 | 76469 | — | Sale at price 10.03 per share. | SIMPSON CURRAN M | Chief Executive Officer | — | 2025-09-29 00:00:00 | D |
| 8 | 7734 | 77495 | — | Sale at price 10.02 per share. | SIMPSON CURRAN M | Chief Executive Officer | — | 2025-09-10 00:00:00 | D |
| 9 | 7768 | — | — | Stock Award(Grant) at price 0.00 per share. | STUMP DAVID CARTER | Director | — | 2025-05-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 6.53K | 1.61K | 647.82K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.09 |
| NormalizedEBITDA | -214.86M | -250.78M | -249.62M | 170.26M |
| TotalUnusualItems | 16.63M | 11.32M | 5.38M | 6.83M |
| TotalUnusualItemsExcludingGoodwill | 16.63M | 11.32M | 5.38M | 6.83M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -227.10M | -263.49M | -280.32M | 127.84M |
| ReconciledDepreciation | 16.21M | 17.32M | 12.91M | 9.56M |
| ReconciledCostOfRevenue | 33.57M | 37.21M | 54.55M | 51.83M |
| EBITDA | -198.23M | -239.46M | -244.24M | 177.09M |
| EBIT | -214.44M | -256.78M | -257.15M | 167.52M |
| NetInterestIncome | -12.48M | -6.84M | -22.91M | -25.56M |
| InterestExpense | 12.66M | 6.86M | 23.25M | 26.28M |
| InterestIncome | 174.00K | 25.00K | 342.00K | 719.00K |
| NormalizedIncome | -243.73M | -274.81M | -285.70M | 121.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -227.10M | -263.49M | -280.32M | 127.84M |
| TotalExpenses | 314.57M | 358.37M | 375.60M | 310.37M |
| TotalOperatingIncomeAsReported | -233.35M | -268.13M | -262.88M | 159.98M |
| DilutedAverageShares | 49.51M | 43.73M | 43.15M | 43.91M |
| BasicAverageShares | 49.51M | 43.73M | 43.15M | 42.44M |
| DilutedEPS | -4.59 | -6.02 | -6.50 | 2.91 |
| BasicEPS | -4.59 | -6.02 | -6.50 | 3.01 |
| DilutedNIAvailtoComStockholders | -227.10M | -263.49M | -280.32M | 127.84M |
| NetIncomeCommonStockholders | -227.10M | -263.49M | -280.32M | 127.84M |
| NetIncome | -227.10M | -263.49M | -280.32M | 127.84M |
| NetIncomeIncludingNoncontrollingInterests | -227.10M | -263.49M | -280.32M | 127.84M |
| NetIncomeContinuousOperations | -227.10M | -263.49M | -280.32M | 127.84M |
| TaxProvision | 0.00 | -152.00K | -84.00K | 13.41M |
| PretaxIncome | -227.10M | -263.65M | -280.40M | 141.25M |
| OtherIncomeExpense | 16.63M | 11.32M | 5.38M | 6.83M |
| SpecialIncomeCharges | -2.10M | 0.00 | 0.00 | |
| ImpairmentOfCapitalAssets | 2.10M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 18.73M | 11.32M | 5.38M | 6.83M |
| NetNonOperatingInterestIncomeExpense | -12.48M | -6.84M | -22.91M | -25.56M |
| InterestExpenseNonOperating | 12.66M | 6.86M | 23.25M | 26.28M |
| InterestIncomeNonOperating | 174.00K | 25.00K | 342.00K | 719.00K |
| OperatingIncome | -231.25M | -268.13M | -262.88M | 159.98M |
| OperatingExpense | 281.01M | 321.16M | 321.06M | 258.53M |
| OtherOperatingExpenses | 865.00K | 397.00K | -6.68M | 333.00K |
| ProvisionForDoubtfulAccounts | -5.00M | 0.00 | 0.00 | -2.57M |
| ResearchAndDevelopment | 208.52M | 232.27M | 242.45M | 181.44M |
| SellingGeneralAndAdministration | 76.62M | 88.49M | 85.28M | 79.33M |
| GeneralAndAdministrativeExpense | 76.62M | 88.49M | 85.28M | 79.33M |
| OtherGandA | 76.62M | 88.49M | 85.28M | 79.33M |
| GrossProfit | 49.76M | 53.03M | 58.18M | 418.51M |
| CostOfRevenue | 33.57M | 37.21M | 54.55M | 51.83M |
| TotalRevenue | 83.33M | 90.24M | 112.72M | 470.35M |
| OperatingRevenue | 83.33M | 90.24M | 112.72M | 470.35M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 49.55M | 44.05M | 43.30M | 42.83M |
| ShareIssued | 49.55M | 44.05M | 43.30M | 42.83M |
| TotalDebt | 82.03M | 89.29M | 94.80M | 86.68M |
| TangibleBookValue | 259.65M | 311.74M | 516.20M | 764.30M |
| InvestedCapital | 259.65M | 311.74M | 516.20M | 764.30M |
| WorkingCapital | 174.81M | 204.70M | 285.54M | 388.35M |
| NetTangibleAssets | 259.65M | 311.74M | 516.20M | 764.30M |
| CapitalLeaseObligations | 82.03M | 89.29M | 94.80M | 86.68M |
| CommonStockEquity | 259.65M | 311.74M | 516.20M | 764.30M |
| TotalCapitalization | 259.65M | 311.74M | 516.20M | 764.30M |
| TotalEquityGrossMinorityInterest | 259.65M | 311.74M | 516.20M | 764.30M |
| StockholdersEquity | 259.65M | 311.74M | 516.20M | 764.30M |
| GainsLossesNotAffectingRetainedEarnings | -741.00K | -4.43M | -15.40M | -2.57M |
| RetainedEarnings | -932.15M | -705.05M | -441.55M | -161.23M |
| AdditionalPaidInCapital | 1.19B | 1.02B | 973.14M | 928.10M |
| CapitalStock | 5.00K | 4.00K | 4.00K | 4.00K |
| CommonStock | 5.00K | 4.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 206.34M | 262.23M | 317.07M | 349.61M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 103.14M | 131.96M | 186.64M | 219.13M |
| OtherNonCurrentLiabilities | 29.01M | 49.73M | 97.84M | 134.21M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 74.13M | 82.22M | 88.80M | 84.93M |
| LongTermCapitalLeaseObligation | 74.13M | 82.22M | 88.80M | 84.93M |
| CurrentLiabilities | 103.19M | 130.27M | 130.43M | 130.47M |
| OtherCurrentLiabilities | 34.31M | 50.57M | 48.60M | 37.89M |
| CurrentDeferredLiabilities | 115.00K | 148.00K | 1.83M | 3.33M |
| CurrentDeferredRevenue | 115.00K | 148.00K | 1.83M | 3.33M |
| CurrentDebtAndCapitalLeaseObligation | 7.90M | 7.07M | 6.00M | 1.75M |
| CurrentCapitalLeaseObligation | 7.90M | 7.07M | 6.00M | 1.75M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 17.61M | 18.15M | 18.07M | 19.85M |
| PayablesAndAccruedExpenses | 43.26M | 54.34M | 55.94M | 67.65M |
| CurrentAccruedExpenses | 20.46M | 31.56M | 28.72M | 44.94M |
| Payables | 22.80M | 22.79M | 27.21M | 22.71M |
| TotalTaxPayable | 0.00 | 11.32M | ||
| IncomeTaxPayable | 0.00 | 11.32M | ||
| AccountsPayable | 22.80M | 22.79M | 27.21M | 11.39M |
| TotalAssets | 465.99M | 573.97M | 833.27M | 1.11B |
| TotalNonCurrentAssets | 187.99M | 239.00M | 417.29M | 595.08M |
| OtherNonCurrentAssets | 6.03M | 6.84M | 8.43M | 8.46M |
| NonCurrentAccountsReceivable | 474.00K | 701.00K | 1.50M | 2.26M |
| InvestmentsAndAdvances | 10.18M | 38.87M | 200.56M | 391.91M |
| InvestmentinFinancialAssets | 10.18M | 38.87M | 200.56M | 391.91M |
| AvailableForSaleSecurities | 10.18M | 38.87M | 200.56M | 391.91M |
| NetPPE | 171.31M | 192.59M | 206.80M | 192.45M |
| AccumulatedDepreciation | -72.29M | -57.21M | -41.39M | -29.04M |
| GrossPPE | 243.60M | 249.80M | 248.19M | 221.49M |
| Leases | 101.47M | 101.93M | 99.40M | 92.53M |
| OtherProperties | 130.86M | 136.12M | 136.92M | 117.88M |
| MachineryFurnitureEquipment | 11.28M | 11.75M | 11.88M | 11.07M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 278.00M | 334.97M | 415.98M | 518.83M |
| OtherCurrentAssets | 12.68M | 18.85M | 7.14M | 10.20M |
| PrepaidAssets | 9.07M | 14.52M | 13.90M | 18.75M |
| Receivables | 21.57M | 26.34M | 30.29M | 32.44M |
| ReceivablesAdjustmentsAllowances | 0.00 | -4.59M | 0.00 | 0.00 |
| OtherReceivables | 20.41M | 24.52M | 27.80M | 32.07M |
| AccruedInterestReceivable | 1.09M | 1.55M | 2.21M | |
| AccountsReceivable | 65.00K | 4.85M | 280.00K | 365.00K |
| AllowanceForDoubtfulAccountsReceivable | -4.59M | 0.00 | ||
| GrossAccountsReceivable | 65.00K | 4.85M | 280.00K | |
| CashCashEquivalentsAndShortTermInvestments | 234.69M | 275.26M | 364.64M | 457.44M |
| OtherShortTermInvestments | 177.16M | 240.74M | 267.69M | 112.23M |
| CashAndCashEquivalents | 57.53M | 34.52M | 96.95M | 345.21M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -175.56M | -228.37M | -238.21M | 134.70M |
| IssuanceOfCapitalStock | 132.26M | 6.70M | 1.74M | 218.21M |
| CapitalExpenditure | -2.44M | -9.96M | -30.72M | -84.17M |
| InterestPaidSupplementalData | 6.56M | 7.28M | 23.12M | 21.64M |
| IncomeTaxPaidSupplementalData | 11.81M | 6.00M | ||
| EndCashPosition | 59.56M | 36.55M | 98.98M | 347.24M |
| BeginningCashPosition | 36.55M | 98.98M | 347.24M | 339.76M |
| ChangesInCash | 23.00M | -62.43M | -248.26M | 7.48M |
| FinancingCashFlow | 92.68M | -34.97M | -28.84M | 195.25M |
| CashFlowFromContinuingFinancingActivities | 92.68M | -34.97M | -28.84M | 195.25M |
| NetOtherFinancingCharges | -41.09M | -43.19M | -33.39M | -27.24M |
| ProceedsFromStockOptionExercised | 1.51M | 1.52M | 2.80M | 4.28M |
| NetCommonStockIssuance | 132.26M | 6.70M | 1.74M | 218.21M |
| CommonStockIssuance | 132.26M | 6.70M | 1.74M | 218.21M |
| InvestingCashFlow | 103.45M | 190.94M | -11.93M | -406.64M |
| CashFlowFromContinuingInvestingActivities | 103.45M | 190.94M | -11.93M | -406.64M |
| NetInvestmentPurchaseAndSale | 105.88M | 200.90M | 18.80M | -322.47M |
| SaleOfInvestment | 296.02M | 287.47M | 203.67M | 175.68M |
| PurchaseOfInvestment | -190.14M | -86.56M | -184.88M | -498.14M |
| NetPPEPurchaseAndSale | -2.44M | -9.96M | -30.72M | -84.17M |
| PurchaseOfPPE | -2.44M | -9.96M | -30.72M | -84.17M |
| OperatingCashFlow | -173.12M | -218.41M | -207.49M | 218.88M |
| CashFlowFromContinuingOperatingActivities | -173.12M | -218.41M | -207.49M | 218.88M |
| ChangeInWorkingCapital | 5.53M | -10.89M | 13.98M | 40.22M |
| ChangeInOtherWorkingCapital | -33.00K | -1.51M | -1.17M | -899.00K |
| ChangeInOtherCurrentLiabilities | -10.69M | -9.16M | 7.57M | 12.36M |
| ChangeInOtherCurrentAssets | 13.51M | -3.19M | 4.73M | -4.72M |
| ChangeInPayablesAndAccruedExpense | -12.42M | -339.00K | -6.83M | 27.60M |
| ChangeInAccruedExpense | -12.12M | 2.45M | -25.62M | 29.91M |
| ChangeInPayable | -292.00K | -2.79M | 18.79M | -2.30M |
| ChangeInAccountPayable | -292.00K | -2.79M | 18.79M | -2.30M |
| ChangeInPrepaidAssets | 5.45M | -620.00K | 4.85M | -8.25M |
| ChangeInReceivables | 9.71M | 3.94M | 4.82M | 14.12M |
| ChangesInAccountReceivables | 9.71M | 3.94M | 4.82M | 14.12M |
| OtherNonCashItems | 7.42M | -95.00K | 368.00K | 4.36M |
| StockBasedCompensation | 38.46M | 40.27M | 40.79M | 38.81M |
| ProvisionandWriteOffofAssets | -5.00M | 0.00 | 0.00 | -2.57M |
| AssetImpairmentCharge | 2.10M | 0.00 | 0.00 | |
| AmortizationOfSecurities | -4.14M | 687.00K | 4.71M | 5.84M |
| DepreciationAmortizationDepletion | 16.21M | 17.32M | 12.91M | 9.56M |
| DepreciationAndAmortization | 16.21M | 17.32M | 12.91M | 9.56M |
| OperatingGainsLosses | -6.62M | -2.21M | 79.00K | -5.19M |
| GainLossOnInvestmentSecurities | -6.62M | -2.21M | 79.00K | -5.19M |
| NetIncomeFromContinuingOperations | -227.10M | -263.49M | -280.32M | 127.84M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RGNX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|